Cytokinetics - CYTK Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued twelve-month price objectives for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they predict the company's share price to reach $57.21 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK shares have decreased by 23.2% and is now trading at $35.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our CYTK earnings forecast.

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, missing analysts' consensus estimates of ($1.22) by $0.23. The biopharmaceutical company earned $1.96 million during the quarter, compared to the consensus estimate of $7.10 million. Cytokinetics had a negative trailing twelve-month return on equity of 1,401.63% and a negative net margin of 410.89%. The company's revenue for the quarter was down 96.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.36) earnings per share.

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Global X Guru Index ETF (GURU), American Century Mid Cap Growth Impact (MID), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

Cytokinetics updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.00 million-$5.00 million.

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Lord Abbett & CO. LLC (3.09%), Geode Capital Management LLC (1.75%), American Century Companies Inc. (1.25%), Price T Rowe Associates Inc. MD (1.17%), Franklin Resources Inc. (1.17%) and Marshall Wace LLP (1.07%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $35.19.

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.36 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis.

The company employs 253 workers across the globe.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.